Monday, May 2, 2016

Canaccord ups Spectranetics price target to $23.50

Canaccord ups Spectranetics price target to $23.50

April 29, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday. “Our bullish conviction heading into the Q1 print was validated by the strong quarterly performance that reflected a continuation of the positive trends from the second half of 2015,” writes analyst Jason Mills. […]

Ocular Therapeutix to initiate Phase 3 program with OTX-TP

Ocular Therapeutix to initiate Phase 3 program with OTX-TP

April 27, 2016 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) has completed an end-of-Phase 2 review with the FDA for its sustained release travoprost product candidate, OTX-TP, for the treatment of glaucoma and ocular hypertension and intends to initiate the first of two Phase 3 clinical trials during the third quarter of 2016. The FDA has stated that it agrees with […]

Novadaq posts 52% jump in Q1 revenue

Novadaq posts 52% jump in Q1 revenue

April 27, 2016 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago. Total direct sales in the quarter rose by $6.1-million, or 71%, and total partnered/international sales declined by $100,000, compared with the year earlier period. The company estimates that the number of procedures performed using SPY technology systems […]

HCW starts Strongbridge Biopharma at buy

HCW starts Strongbridge Biopharma at buy

April 27, 2016 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively […]

Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics begins Phase 2 SARM study

April 26, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have […]

Leerink downgrades Trovagene to market perform

Leerink downgrades Trovagene to market perform

April 26, 2016 by · Leave a Comment 

Tweet Leerink Partners has downgraded Trovagene (NASDAQ:TROV) to “market perform” from “outperform” and lowered its price target to $4.50 from $8, following the recent removal/departure of key senior management. The stock closed at $4.73 on Monday. “While we remain intrigued by Trovagene’s opportunity in liquid biopsy, a large part of our investment thesis rested on […]

Opioid addiction treatment continues to grab headlines

Opioid addiction treatment continues to grab headlines

April 22, 2016 by · Leave a Comment 

Tweet An article in the latest issue of Guernica, a magazine of art and politics, details the plight of doctors prescribing buprenorphine, a medication for the treatment of opiate addiction. Unlike methadone, buprenorphine was approved for use in a general office setting. A doctor can apply to get a waiver to prescribe buprenorphine and treat […]

BTIG ups Cerus price target to $10

BTIG ups Cerus price target to $10

April 22, 2016 by · Leave a Comment 

Tweet BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday. Cerus is a biomedical products company focused on the field of blood safety. “We are now lowering our discount rate […]

HCW starts Windtree Therapeutics at buy

HCW starts Windtree Therapeutics at buy

April 22, 2016 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Windtree Therapeutics (NASDAQ:WINT) with a “buy” rating and $8 price target, ahead of study readouts on tap for the next 12 months. The stock closed at $3.03 on Thursday. “We believe that the company’s investigational drug/device combination, Aerosurf, which aims to deliver aerosolized surfactant to neonates with respiratory […]

Stifel starts Celator Pharma at buy

Stifel starts Celator Pharma at buy

April 22, 2016 by · Leave a Comment 

Tweet Stifel has initiated coverage of Celator Pharmaceuticals (NASDAQ:CPXX) with a “buy” rating and a 12-month target price of $23. The stock closed at $15.52 on Thursday. Analyst Stephen Willey writes that recently-announced Phase 3 data, demonstrating Vyxeos confers a statistically-significant improvement in overall survival versus traditional cytarabine/daunorubicin chemotherapy (“7+3”) in patients aged 60-to-75 with […]

Next Page »

Email Newsletters with Constant Contact
Google+